Considerations for use of avian influenza A(‎H5)‎ vaccines during the interpandemic and emergence periods: report of a WHO virtual scientific consulta

[Pathfinder]

Considerations for use of avian influenza A(‎H5)‎ vaccines during the interpandemic and emergence periods: report of a WHO virtual scientific consultation, September 2024

23 June 2025
| Technical document​

Download (851.6 kB)

Overview

WHO conducted a virtual scientific expert consultation on A(H5) vaccines and vaccination. This report provides an overview of the landscape of A(H5) vaccines and summarizes options for Member States' potential use of A(H5) vaccination during the interpandemic and emergence periods.​

https://www.who.int/publications/i/item/9789240111462

 

[Commonground]

from above report:

Summary of the evidence of development pipeline for new A(H5) vaccines

Table 4 shows the development pipeline for new A(H5) vaccines as of April 2025 (21–29). In contrast to currently

licensed seasonal influenza vaccines, this pipeline shows a shift towards newer vaccine platforms and manufacturing

technologies. Two IIV candidates are egg-based, while other IIV candidates are cell-based, along with three

recombinant hemagglutinin protein vaccines. Of these new developments, messenger ribonucleic acid (mRNA)

vaccine candidates comprise about half of the pipeline; these are manufactured synthetically. A(H5) mRNA vaccine

candidates are in various stages of development including vaccine products now entering phase III clinical trials.

​